GlassScriptPhysician profile
Julie Stancliff
NPI 1366656340
$57,338.40
in general payments reported to CMS, 2019-2025
14 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $6,584 · 2021: $19K · 2022: $9,731 · 2023: $3,842 · 2024: $216 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,380 · Food and Beverage: $737 · Travel and Lodging: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,380.00 |
| Food and Beverage | $737.33 |
| Travel and Lodging | $166.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $56,133.07 | 2019-2024 | Vivitrol, Aristada, Lybalvi |
| Abbvie INC. | $265.57 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.00 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $137.73 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $125.82 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $111.06 | 2021-2022 | |
| Uswm, LLC | $104.92 | 2022-2023 | Lucemyra, Zimhi |
| Vanda Pharmaceuticals INC. | $90.46 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $67.94 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $58.99 | 2021-2025 | |
| Lundbeck LLC | $41.98 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $23.29 | 2023 | Auvelity |
| Corium, LLC | $18.12 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.45 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Stancliff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.